Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lucemyra (Lofexidine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Substance Withdrawal Syndrome.
Product Name : Lucemyra
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Panbela Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CPP-1X-T (eflornithine) is a single agent tablet or high dose powder sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes. It is approved by USFDA for the treatment of Pediatri...
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Panbela Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Product Name : Iwilfin
Product Type : Amino Acid
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Eflornithine for Adult and Pediatric Patients with High-Risk Neuroblastoma
Details : Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).
Product Name : Iwilfin
Product Type : Amino Acid
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lofexidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Substance Withdrawal Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Panbela Therapeutics
Deal Size : $9.5 million
Deal Type : Divestment
Details : Panbela has divested certain assets in its eflornithine pediatric neuroblastoma program including, CPP-1X (eflornithine), being developed for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 d...
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Undisclosed
July 19, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Panbela Therapeutics
Deal Size : $9.5 million
Deal Type : Divestment
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Adamis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI Naloxone Product
Details : ZIMHI represents a new tool for patients by combining an intuitive, compact, and simple to use intramuscular device with a high dose of naloxone. Successfully treating overdoses involving fentanyl often requires multiple doses of lower-dose or intranasal...
Product Name : Zimhi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Adamis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Norgine Enter Agreement to Commercialise DFMO in Independent States
Details : DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality thera...
Product Name : Iwilfin
Product Type : Amino Acid
Upfront Cash : Undisclosed
July 23, 2021
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Norgine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Federal Emergency Management Agency
Deal Size : Undisclosed
Deal Type : Partnership
US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic
Details : US WorldMeds, in conjunction with FEMA and their partnership with Healthcare Ready, is making a donation of LUCEMYRA valued at approximately $100,000 to NorthLakes Community Clinic, a federally qualified health center located in northern Wisconsin.
Product Name : Lucemyra
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 06, 2020
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Federal Emergency Management Agency
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds
Details : This acquisition significantly expands Supernus' business in CNS and increases and diversifies its revenue and earnings streams, while continuing to maintain a strong balance sheet.
Product Name : Apokyn
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 09, 2020
Lead Product(s) : Apomorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition